Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01MH114544 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Wits Reproductive Health and HIV Institute | OTHER |
| National Institute of Mental Health (NIMH) | NIH |
Not provided
Not provided
Not provided
Not provided
The PrEP SMART study is testing a stepped model of scalable adherence support strategies in South African young women who initiate PrEP using a SMART (sequential multiple assignment randomized trial) design.
Women enrolled in the study will be randomized to standard of care adherence support (brief counseling) and either WhatsApp groups or weekly two-way SMS messages. Two months after PrEP initiation, tenofovir drug levels will be measured to determine if participants have achieved high adherence based on their initial randomization. Women with high adherence (i.e., TFV-DP >/=500 fmol/punch from dried blood spots [DBS]) will continue with the adherence support to which they were initially randomized. Participants with low adherence (i.e., TFV-DP <500 fmol/punch from DBS) will continue initial randomization (WhatsApp or two-way SMS) plus be randomized to more one of two more intensive adherence support interventions - continued monthly visits with adherence and problem-focused counseling at months 3-8 or quarterly visits between months 3-9 with feedback about adherence based on drug levels at months 3 and 6.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WhatsApp Group | Experimental | Participants will be assigned to participate in a WhatsApp Group |
|
| 2-way SMS | Experimental | Participants will be assigned to receive weekly 2-way SMS initiated by the study team |
|
| 2-way SMS and monthly counseling sessions | Experimental | Participants will be assigned to receive weekly 2-way SMS initiated by the study team and monthly counseling sessions |
|
| 2-way SMS and drug level feedback | Experimental | Participants will be assigned to receive weekly 2-way SMS initiated by the study team and drug level feedback |
|
| WhatsApp Group and monthly counseling sessions | Experimental | Participants will be assigned to participate in a WhatsApp Group and monthly counseling sessions |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WhatsApp Group | Behavioral | Participants will receive peer adherence support through WhatsApp groups |
|
| Measure | Description | Time Frame |
|---|---|---|
| PrEP Adherence | Evaluation of the proportion of young women who adhere well to PrEP in each of the original intervention arms. | 9 months |
| Measure | Description | Time Frame |
|---|---|---|
| Probability of High PrEP Adherence at Nine Months | Estimated probability of high PrEP adherence (tenofovir diphosphate levels greater than or equal to 700 fmol/punch at 9 months) by embedded dynamic treatment strategy. This analysis employed a weighted and replicated approach to account for non-response, re-randomization, and overlap in intervention assignments (e.g., the same participants in the SMS intervention were represented twice in two of the four interventions). Weighting accounted for over-representation of people who responded, whereas replicating responder observations across the two embedded dynamic treatment strategies with the same first-line treatment accounted for one participant being able to be in two treatment strategies. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Connie Celum, MD, MPH | University of Washington | Principal Investigator |
| Sinead Delany-Moretlwe, MBChB, PhD | Wits Reproductive Health and HIV Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Wits Reproductive Health and HIV Institute | Johannesburg | South Africa |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39681126 | Derived | Velloza J, Poovan N, Meisner A, Ndlovu N, Ndimande-Khoza N, Grabow C, Zwane P, Mbele S, Molefe M, Donnell D, Baeten JM, Hosek S, Celum C, Delany-Moretlwe S. Adaptive HIV pre-exposure prophylaxis adherence interventions for young women in Johannesburg, South Africa: a sequential multiple-assignment randomised trial. Lancet HIV. 2025 Feb;12(2):e105-e117. doi: 10.1016/S2352-3018(24)00268-6. Epub 2024 Dec 13. | |
| 35417485 | Derived | Velloza J, Poovan N, Ndlovu N, Khoza N, Morton JF, Omony J, Mkwanazi E, Grabow C, Donnell D, Munthali R, Baeten JM, Hosek S, Celum C, Delany-Moretlwe S. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial. PLoS One. 2022 Apr 13;17(4):e0266665. doi: 10.1371/journal.pone.0266665. eCollection 2022. |
Not provided
Not provided
Data from the PrEP SMART Study will be available at the end of the project by contacting the Principal Investigators.
Not provided
Not provided
Not provided
Not provided
Participants were initially randomized to either 2 way SMS or the WhatsApp group. At the M3 follow up visit participants who were no responders to the primary randomization were then randomized to either drug level feedback counseling or monthly counseling visits.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 2-way SMS Responders (no Second Randomization) | Participants will be assigned to receive weekly 2-way SMS initiated by the study team 2-way SMS: Participants will receive healthcare worker adherence support through 2-way SMS |
| FG001 | WhatsApp Group Responders (no Second Randomization) | Participants will be assigned to participate in a WhatsApp Group WhatsApp Group: Participants will receive peer adherence support through WhatsApp groups |
| FG002 | 2-way SMS Plus Drug Level Feedback Non Responders | Participants were originally assigned to 2-way SMS but were randomized again at M3 to receive adherence counseling based on tenofovir drug levels |
| FG003 | 2-way SMS Plus Monthly Counseling Sessions Non-responders | Participants were originally assigned to receive weekly 2-way SMS initiated by the study team, at M3 they were assigned monthly counseling sessions on a variety of issues that may be impacting their PrEP adherence. |
| FG004 | WhatsApp Group Plus Drug Level Feedback Non-responders | Participants were originally assigned to participate in a WhatsApp Group and at M3 were assigned to receive adherence counseling based on tenofovir drug levels. |
| FG005 | WhatsApp Group Plus Monthly Counseling Sessions Non-responders | Participants were assigned to participate in a WhatsApp Group and at M3 were assigned to receive monthly counseling sessions on a variety of issues that may be impacting their PrEP adherence. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Month 0 - Month 3 |
| |||||||||||||
| Month 3 - Month 9 |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 2-Way SMS | Participants in this arm will be randomized to receive 2-way SMS. If at 3 months they are responding they continue in their original arm. If non-responding, they have an additional randomization to monthly counseling visits or drug-level feedback counseling. |
| BG001 | WhatsApp Groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | PrEP Adherence | Evaluation of the proportion of young women who adhere well to PrEP in each of the original intervention arms. | The results show the number of participants who had TFV-DP results of greater than or equal to 700 fmol/punch at their 9 month visit, based on their original randomization arm. | Posted | Count of Participants | Participants | 9 months |
|
9 months of follow up
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 2-Way SMS | Participants in this arm will be randomized to receive 2-way SMS. If at 3 months they are responding they continue in their original arm. If non-responding, they have an additional randomization to monthly counseling visits or drug-level feedback counseling. |
Not provided
Not provided
Future work is needed to assess optimal approaches for implementing WhatsApp adherence clubs as an alternative support group model. Although the two-way SMS and WhatsApp support groups involved less participant burden and clinic-based procedures than the counseling interventions, they were still time-intensive for staff monitoring the messages. Future PrEP implementation programs considering these approaches will need to decide what level of messaging and phone-based follow-up is feasible.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Jennifer Velloza | University of California San Francisco | 917 392 3561 | jennifer.velloza@ucsf.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Aug 26, 2020 | Dec 14, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 9, 2022 | Dec 14, 2023 | SAP_001.pdf |
| ICF | No | No | Yes | Informed Consent Form | Aug 26, 2020 | Dec 14, 2023 | ICF_002.pdf |
Not provided
| ID | Term |
|---|---|
| D000163 | Acquired Immunodeficiency Syndrome |
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Sequential multiple assignment randomized trial (SMART)
Not provided
Not provided
Not provided
| WhatsApp Group and drug level feedback | Experimental | Participants will be assigned to participate in a WhatsApp Group and drug level feedback |
|
| 2-way SMS | Behavioral | Participants will receive healthcare worker adherence support through 2-way SMS |
|
| Drug level feedback | Behavioral | Participants will receive adherence counseling based on tenofovir drug levels |
|
| Monthly counseling sessions | Behavioral | Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence |
|
| 9 months |
| PrEP Discontinuation | Assessment of the timing of PrEP discontinuation in young women who discontinue PrEP, reported by original intervention arm. | 9 months |
| COMPLETED |
|
| NOT COMPLETED |
|
Participants in this arm will be randomized to join a WhatsApp group. If at 3 months they are responding they continue in their original arm. If non-responding, they have an additional randomization to monthly counseling visits or drug-level feedback counseling. |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Median | Inter-Quartile Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Participants in this arm will be randomized to join a WhatsApp group. If at 3 months they are responding they continue in their original arm. If non-responding, they have an additional randomization to monthly counseling visits or drug-level feedback counseling.
|
|
| Secondary | Probability of High PrEP Adherence at Nine Months | Estimated probability of high PrEP adherence (tenofovir diphosphate levels greater than or equal to 700 fmol/punch at 9 months) by embedded dynamic treatment strategy. This analysis employed a weighted and replicated approach to account for non-response, re-randomization, and overlap in intervention assignments (e.g., the same participants in the SMS intervention were represented twice in two of the four interventions). Weighting accounted for over-representation of people who responded, whereas replicating responder observations across the two embedded dynamic treatment strategies with the same first-line treatment accounted for one participant being able to be in two treatment strategies. | Analysis conducted among all participants who were retained and had data at Month 9. Population includes responders and non-responders to compare flow of outcomes among simulated population. Participants are grouped by embedded dynamic treatment strategy. See Outcome Measure Description for notes on weighting and double-counting. | Posted | Number | 95% Confidence Interval | Probability of high PrEP Adherence | 9 months |
|
|
|
| Secondary | PrEP Discontinuation | Assessment of the timing of PrEP discontinuation in young women who discontinue PrEP, reported by original intervention arm. | Number of participants who had at least one PrEP discontinuation at Month 9, reported by original randomization group. | Posted | Count of Participants | Participants | 9 months |
|
|
|
| 0 |
| 180 |
| 0 |
| 180 |
| 0 |
| 180 |
| EG001 | WhatsApp Groups | Participants in this arm will be randomized to join a WhatsApp group. If at 3 months they are responding they continue in their original arm. If non-responding, they have an additional randomization to monthly counseling visits or drug-level feedback counseling. | 0 | 180 | 0 | 180 | 0 | 180 |
Not provided
Not provided
Not provided
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |